MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York.
| Revenue (Most Recent Fiscal Year) | $33.28M |
| Net Income (Most Recent Fiscal Year) | $-147.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 12.48 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 13.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -484.90% |
| Net Margin (Trailing 12 Months) | -484.90% |
| Return on Equity (Trailing 12 Months) | -241.05% |
| Return on Assets (Trailing 12 Months) | -62.93% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.51 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.34 |
| Inventory Turnover (Trailing 12 Months) | 101.49 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.51 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 80.36M |
| Free Float | 74.34M |
| Market Capitalization | $430.76M |
| Average Volume (Last 20 Days) | 0.63M |
| Beta (Past 60 Months) | 1.30 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 67.48% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |